Summary | |
---|---|
Symbol | HMGN1 |
Name | high mobility group nucleosome binding domain 1 |
Aliases | FLJ27265; FLJ31471; MGC104230; MGC117425; high-mobility group nucleosome binding 1; nonhistone chromosomal p ...... |
Chromosomal Location | 21q22.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway |
Subcellular Location | Nucleus. Cytoplasm. Note=Cytoplasmic enrichment upon phosphorylation. The RNA edited version localizes to the nucleus. |
Domain |
PF01101 HMG14 and HMG17 |
Function |
Binds to the inner side of the nucleosomal DNA thus altering the interaction between the DNA and the histone octamer. May be involved in the process which maintains transcribable genes in a unique chromatin conformation. Inhibits the phosphorylation of nucleosomal histones H3 and H2A by RPS6KA5/MSK1 and RPS6KA3/RSK2 (By similarity). |
Biological Process |
GO:0000720 pyrimidine dimer repair by nucleotide-excision repair GO:0001654 eye development GO:0006283 transcription-coupled nucleotide-excision repair GO:0006289 nucleotide-excision repair GO:0006290 pyrimidine dimer repair GO:0006354 DNA-templated transcription, elongation GO:0007423 sensory organ development GO:0009314 response to radiation GO:0009411 response to UV GO:0009416 response to light stimulus GO:0009791 post-embryonic development GO:0009886 post-embryonic animal morphogenesis GO:0010224 response to UV-B GO:0010225 response to UV-C GO:0031077 post-embryonic camera-type eye development GO:0032784 regulation of DNA-templated transcription, elongation GO:0032786 positive regulation of DNA-templated transcription, elongation GO:0040034 regulation of development, heterochronic GO:0043010 camera-type eye development GO:0048050 post-embryonic eye morphogenesis GO:0048563 post-embryonic animal organ morphogenesis GO:0048569 post-embryonic animal organ development GO:0048592 eye morphogenesis GO:0048593 camera-type eye morphogenesis GO:0048597 post-embryonic camera-type eye morphogenesis GO:0050673 epithelial cell proliferation GO:0050678 regulation of epithelial cell proliferation GO:0090596 sensory organ morphogenesis GO:1901664 regulation of NAD+ ADP-ribosyltransferase activity GO:1901666 positive regulation of NAD+ ADP-ribosyltransferase activity |
Molecular Function |
GO:0003682 chromatin binding GO:0031490 chromatin DNA binding GO:0031491 nucleosome binding GO:0031492 nucleosomal DNA binding GO:0043566 structure-specific DNA binding |
Cellular Component |
GO:0000785 chromatin |
KEGG | - |
Reactome |
R-HSA-73894: DNA Repair R-HSA-6782135: Dual incision in TC-NER R-HSA-6781823: Formation of TC-NER Pre-Incision Complex R-HSA-6782210: Gap-filling DNA repair synthesis and ligation in TC-NER R-HSA-5696398: Nucleotide Excision Repair R-HSA-6781827: Transcription-Coupled Nucleotide Excision Repair (TC-NER) |
Summary | |
---|---|
Symbol | HMGN1 |
Name | high mobility group nucleosome binding domain 1 |
Aliases | FLJ27265; FLJ31471; MGC104230; MGC117425; high-mobility group nucleosome binding 1; nonhistone chromosomal p ...... |
Chromosomal Location | 21q22.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Literatures that report relations between HMGN1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells. |
Literatures describing the relation between HMGN1 and anti-tumor immunity in human cancer.
|
Summary | |
---|---|
Symbol | HMGN1 |
Name | high mobility group nucleosome binding domain 1 |
Aliases | FLJ27265; FLJ31471; MGC104230; MGC117425; high-mobility group nucleosome binding 1; nonhistone chromosomal p ...... |
Chromosomal Location | 21q22.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets. |
> High-throughput Screening
[ TOP ]
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Statistical results of HMGN1 in screening data sets for detecting immune reponses.
|
Summary | |
---|---|
Symbol | HMGN1 |
Name | high mobility group nucleosome binding domain 1 |
Aliases | FLJ27265; FLJ31471; MGC104230; MGC117425; high-mobility group nucleosome binding 1; nonhistone chromosomal p ...... |
Chromosomal Location | 21q22.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders |
Points in the above scatter plot represent the expression difference of HMGN1 in various data sets.
|
There is no record. |
Summary | |
---|---|
Symbol | HMGN1 |
Name | high mobility group nucleosome binding domain 1 |
Aliases | FLJ27265; FLJ31471; MGC104230; MGC117425; high-mobility group nucleosome binding 1; nonhistone chromosomal p ...... |
Chromosomal Location | 21q22.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of HMGN1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene. |
Summary | |
---|---|
Symbol | HMGN1 |
Name | high mobility group nucleosome binding domain 1 |
Aliases | FLJ27265; FLJ31471; MGC104230; MGC117425; high-mobility group nucleosome binding 1; nonhistone chromosomal p ...... |
Chromosomal Location | 21q22.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of HMGN1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by HMGN1. > Immunoinhibitor > Immunostimulator > MHC molecule |
Summary | |
---|---|
Symbol | HMGN1 |
Name | high mobility group nucleosome binding domain 1 |
Aliases | FLJ27265; FLJ31471; MGC104230; MGC117425; high-mobility group nucleosome binding 1; nonhistone chromosomal p ...... |
Chromosomal Location | 21q22.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of HMGN1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor |
Summary | |
---|---|
Symbol | HMGN1 |
Name | high mobility group nucleosome binding domain 1 |
Aliases | FLJ27265; FLJ31471; MGC104230; MGC117425; high-mobility group nucleosome binding 1; nonhistone chromosomal p ...... |
Chromosomal Location | 21q22.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Distribution of HMGN1 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype |
Summary | |
---|---|
Symbol | HMGN1 |
Name | high mobility group nucleosome binding domain 1 |
Aliases | FLJ27265; FLJ31471; MGC104230; MGC117425; high-mobility group nucleosome binding 1; nonhistone chromosomal p ...... |
Chromosomal Location | 21q22.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Associations between HMGN1 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade |
Summary | |
---|---|
Symbol | HMGN1 |
Name | high mobility group nucleosome binding domain 1 |
Aliases | FLJ27265; FLJ31471; MGC104230; MGC117425; high-mobility group nucleosome binding 1; nonhistone chromosomal p ...... |
Chromosomal Location | 21q22.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Drugs targeting HMGN1 collected from DrugBank database. |
There is no record. |